Due to the expression of CD19 on both normal B cells and malignant tumor cells, long-term B-cell depletion, which is the expected “off-tumor” effect of CD19 CAR-T cells, is a common phenomenon following CD19-targeted CAR-T-cell therapy. This evidence concerns the gene CD19 and neoplasm.